Murray Stahl's REGN Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 675 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $521,532, representing 0.01% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Murray Stahl has maintained a strategic position in REGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 30 shares. Largest reduction occurred in Q4 2023, reducing 30 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -30 | Reduce 4.26% | 675 | $772.64 |
| Q4 2025 | -30 | Reduce 4.08% | 705 | $771.87 |
| Q3 2025 | +30 | Add 4.26% | 735 | $562.27 |
| Q2 2025 | -30 | Reduce 4.08% | 705 | $525.00 |
| Q4 2024 | +29 | Add 4.11% | 735 | $712.33 |
| Q3 2024 | -30 | Reduce 4.08% | 706 | $1051.24 |
| Q1 2024 | +1 | Add 0.14% | 736 | $962.49 |
| Q4 2023 | -30 | Reduce 3.92% | 735 | $878.29 |
| Q1 2023 | +765 | New Buy | 765 | $821.67 |
Murray Stahl's Regeneron Pharmaceuticals Investment FAQs
Murray Stahl first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q1 2023, acquiring 765 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Regeneron Pharmaceuticals, Inc. (REGN) for 13 quarters since Q1 2023.
Murray Stahl's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q1 2023, adding 765 shares worth $628,578.
According to the latest 13F filing for Q1 2026, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 675 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $521,532.
As of the Q1 2026 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.01% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 765 shares, as reported at the end of Q1 2023.